TY - JOUR T1 - Delta-9-Tetrahydrocannabinol/Cannabidiol Oromucosal Spray (Sativex®): A Review in Multiple Sclerosis-Related Spasticity. A1 - Keating,Gillian M, PY - 2017/3/16/pubmed PY - 2017/5/16/medline PY - 2017/3/16/entrez SP - 563 EP - 574 JF - Drugs JO - Drugs VL - 77 IS - 5 N2 - Delta-9-tetrahydrocannabinol (THC)/cannabidiol (CBD) oromucosal spray (THC/CBD, Sativex®, nabiximols) is available in numerous countries worldwide for the treatment of multiple sclerosis (MS)-related moderate to severe spasticity in patients who have not responded adequately to other anti-spasticity medication and who demonstrate clinically significant improvement in spasticity-related symptoms during an initial trial of therapy. Twelve weeks' therapy with THC/CBD improved MS-related spasticity in patients with an inadequate response to other anti-spasticity agents who had undergone a successful initial trial of THC/CBD therapy, according to the results of a pivotal phase 3 trial. Improvements in spasticity were maintained in the longer term with THC/CBD with no evidence of dose tolerance, and results of real-world studies confirm the effectiveness of THC/CBD in everyday clinical practice. Improvements in health-related quality of life and activities of daily living were also seen with THC/CBD. THC/CBD is generally well tolerated; adverse effects such as dizziness may occur whilst the THC/CBD dosage is being optimized. THC/CBD has low abuse potential and a low risk of psychoactive effects. In conclusion, THC/CBD oromucosal spray is a useful option for the treatment of MS-related spasticity not completely relieved with current anti-spasticity medication. SN - 1179-1950 UR - https://www.unboundmedicine.com/medline/citation/28293911/Delta_9_Tetrahydrocannabinol/Cannabidiol_Oromucosal_Spray__Sativex®_:_A_Review_in_Multiple_Sclerosis_Related_Spasticity_ L2 - https://dx.doi.org/10.1007/s40265-017-0720-6 DB - PRIME DP - Unbound Medicine ER -